Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors
The Pharma Data
JANUARY 18, 2021
From this, BT-001 is engineered to encode both a highly differentiated Treg depleting anti-CTLA4 antibody and the human GM-CSF cytokine. The recombinant antibody recognizing human CTLA4 was generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T Transgene has an ongoing Invir.IO collaboration with AstraZeneca.
Let's personalize your content